Search results

The People’s Republic of China has long craved advanced technologies, and has undertaken an overwhelming number of changes in its intellectual property laws in order to foster domestic innovation and to encourage foreign investment. China implemented its first patent law in 1985. However, implementation and enforcement of this law and its amendments have been difficult, such that many foreign firms are reluctant to invest in Chinese markets. This paper describes the many changes that have been made to Chinese patent laws, and then illustrates patent activity in China as those changes have been implemented. Managerial issues are discussed in detail.

Globalization should provide firms with an opportunity to leverage their know-how and reputation across countries to create value. However, it remains challenging for them to actually capture that value using traditional Intellectual Property (IP) tools. In this paper, we document the strong growth in patents, trademarks, and industrial designs used by firms to protect their IP globally. We then show that IP protection remains fragmented; the quality of IP applications might be questionable; and developing a comprehensive IP footprint worldwide is very costly. Growing numbers of applications are causing backlogs and delays in numerous Patent and Trademarks Offices and litigation over IP rights is expensive, with an uncertain outcome. Moreover, local governments can succeed in transferring value to local firms and influencing global market positions by using IP laws and other regulations. In essence, the analysis shows a global IP environment that leaves much to be desired. Despite these challenges, there are successful strategies to capture value from know-how and reputation by leveraging an array of IP tools. These strategies have important implications for management practice, as we discuss in our concluding section. Global companies will need to organize cross-functional value capture teams focused on appropriating value from their know-how and reputation by combining different institutional, market, and nonmarket tools, depending on the institutional and business environment in a particular region.

To investigate the impact of knowledge-intensive FDI in the Chinese pharmaceutical industry, this study analyzes the activity of foreign MNEs operating in this context by exploring their innovative background, the organizational arrangements they use for local knowledge creation and the performance of their local innovative processes. Based on the analysis of the universe of USPTO pharmaceutical patents applied for between 1975 and 2010 and granted to foreign assignees utilizing the work of Chinese inventors, our results show that, while the presence of foreign MNEs in the Chinese pharmaceutical industry entails a strong potential for positive externalities that could enhance the performance of the local innovation system, such externalities do not completely materialize yet, likely because of local actors’ limited absorptive capacity.

University–industry technology transfer is growing at a rapid rate in China, involving both multinational and domestic companies. This chapter describes unique characteristics of Chinese National Technology Transfer Centers (NTTCs) and examines whether they can function as an effective policy instrument in promoting the commercialization of university research findings. Our qualitative and quantitative study finds that NTTCs are not by themselves an effective policy tool in accelerating the commercialization of university inventions. We found that universities without NTTCs can achieve the same or even greater success than those with NTTCs. We suggest that Chinese universities should mimic the Western approach by providing an attractive reward system and autonomy to technology management programs that stimulate their efforts in marketing patented technology.

This study explores the thematic relationships within the field of sustainability of agri-food chains oriented toward Industry 4.0, focusing on the analysis of scientific production, through research articles and technological output according to patents worldwide. Agri-food Industry 4.0 is an expanding interdisciplinary field in which science and technology interactions are increasingly intensifying with a strong link to sustainable development.

This study has used high impact indexed publications (Web of science) and patents as proxy indicators of innovation, which are transformed into two sets of data, reflecting the scientific and technical backgrounds, respectively. On the one hand, both quantitative and qualitative analysis methodologies were used to examine the scientific papers through descriptive analysis, focused on collaborations networks by authors, institutions, and countries, as well as a content analysis of keywords. On the other hand, the analysis of technical background on patent families shows the temporal evolution of technologies with future challenging trends, text mining, main applicants, and geographical examination.

The results show that in the field of sustainability in agri-food chains oriented to Industry 4.0, most research is in the agricultural field in scientific articles, with high impact in climate-smart agriculture. Patent analysis reveals a marked increase in the patenting rate from 2012 and 2013, coinciding with the start of scientific production in this field of knowledge. In spite of the fact that China is the leader country in this technological field, India shows a significant change. Moreover, India is a country that is currently showing significant progress, both in the field of scientific production and in its categorization as an innovative country due to its growth in patent filings.

The World Health Organization estimated that in 1999 roughly one-third of the world's population lacked access to essential medicines that would have saved or improved their lives. Our analysis focuses on how pharmaceutical product patents restrict access to essential medicines in developing countries. It is well established that pharmaceutical product patents provide little incentive for pharmaceutical companies to develop new medicines designed to treat diseases prevalent in developing countries or to market in developing countries those patented medicines developed to treat diseases prevalent in developed countries. Economists have developed theoretical models showing that these incentives could be changed if (1) developing countries provided intellectual property protection for new pharmaceutical innovations and (2) an international regulatory framework were established to facilitate pharmaceutical companies setting lower prices in developing countries and higher prices in developed countries for patented medicines. We develop an index of property rights in pharmaceutical innovations covering 129 countries from 1960 to 2005. It shows that in 1960 only a handful of countries provided significant protection for pharmaceutical innovations, but by 2005 over 95 percent of countries in our sample provided significant statutory protections. However, an international framework to allow pharmaceutical companies to price discriminate has not been put in place. We conclude that international price discrimination mechanisms, compulsory patent licenses, and regional patent buyouts are not viable mechanisms for providing access to essential medicines to patients in developing countries. Global patent buyouts are more likely to achieve this goal, as they are not founded on an impractical separation of pharmaceutical markets in developing and developed countries and they provide critical incentives to develop new essential medicines.

Purpose – The objective of this chapter is to examine and provide new perspectives on the contributions of public and private R&D to biotech crop improvement.

Methodology/approach – The chapter examines a set of topics that have affected the way that research is undertaken on plant germplasm improvement and how it has changed with the genetically modified (GM) trait revolution.

Findings – Although the basic science providing the foundations for GM crops was undertaken in the public sector, GM traits and GM crop varieties have been developed almost exclusively by the private sector. The biotech events leading to GM traits are currently being developed largely by five companies – all having ties to both the chemical and the seed industries. The GM crop revolution started in North American in 1996 and has spread slowly to the largest developing countries that have large agricultural sectors, including Argentina, China, Brazil, and India, but not to Europe or Japan.

Practical implication – To shed new light on the economic reasons for private sector dominance in GM crop varietal development in selected crops but not in others.

Social implication – Shows how GM traits have contributed to technical change and declining real food prices.